EUCTR2017-004417-42-EE进行中（未招募）1 期
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,955
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Participants are currently enrolled in MSD-sponsored pembrolizumab trials and are receiving trial treatment or in a follow-up phase at the time KN-587 is open. Participants must be from MSD-sponsored pembrolizumab parent trials established by the Sponsor as KN-587 transition-ready.
- •2. The participant (or legally acceptable representative if applicable) provides informed consent for the trial and agrees to follow study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 2100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •There are no exclusion criteria to participate in KN587.
研究者
相似试验
进行中（未招募）
1 期
Extension Study for Participants With Advanced Tumors in Pembrolizumab TrialsAdvanced TumorsMedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2017-004417-42-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,955
进行中（未招募）
1 期
Extension Study for Participants With Advanced Tumors in Pembrolizumab TrialsEUCTR2017-004417-42-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,955
进行中（未招募）
1 期
Extension Study for Participants With Advanced Tumors in Pembrolizumab TrialsEUCTR2017-004417-42-IEMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1,955
进行中（未招募）
1 期
Extension Study for Participants With Advanced Tumors in Pembrolizumab TrialsAdvanced TumorsMedDRA version: 21.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 100000004864EUCTR2017-004417-42-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,955
进行中（未招募）
1 期
Extension Study for Participants With Advanced Tumors in Pembrolizumab TrialsEUCTR2017-004417-42-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,955